[Twenty-seven years' activities of the French vasculitis study group (FVSG)].
Guillevin
L
L
Service de médecine interne, centre de référence des maladies rares, vascularites et sclérodermies, hôpital Cochin, AP-HOP, université Paris-Descartes, 27 rue du Faubourg-Saint-Jacques, 75014 Paris, France. loic.guillevin@cch.ap-hop-paris.fr
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000276:immunology; D000998:Antiviral Agents / Q000627:therapeutic use; D003449:Cryoglobulinemia / Q000188:drug therapy / Q000821:virology; D003520:Cyclophosphamide / Q000627:therapeutic use; D005602:France; D006509:Hepatitis B / Q000150:complications; D006526:Hepatitis C / Q000150:complications; D006801:Humans; D007116:Immunization, Passive; D007155:Immunologic Factors / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D010951:Plasma Exchange; D000069283:Rituximab; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D014657:Vasculitis / Q000188:drug therapy / Q000628:therapy* / Q000821:virology
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000998:Antiviral Agents; D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D000069283:Rituximab; D003520:Cyclophosphamide